Found 11 results
Filters: Keyword is Treatment Outcome  [Clear All Filters]
Journal Article
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint., Swaminathan, Srividya, Huang ChuanXin, Geng Huimin, Chen Zhengshan, Harvey Richard, Kang Huining, Ng Carina, Titz Björn, Hurtz Christian, Sadiyah Mohammed Firas, et al. , Nat Med, 2013 Aug, Volume 19, Issue 8, p.1014-22, (2013)
CD99 is a therapeutic target on disease stem cells in myeloid malignancies., Chung, Stephen S., Eng William S., Hu Wenhuo, Khalaj Mona, Garrett-Bakelman Francine E., Tavakkoli Montreh, Levine Ross L., Carroll Martin, Klimek Virginia M., Melnick Ari M., et al. , Sci Transl Med, 2017 Jan 25, Volume 9, Issue 374, (2017)
Enhancer of zeste homolog 2 (EZH2) inhibitors., Gulati, Nitya, Béguelin Wendy, and Giulino-Roth Lisa , Leuk Lymphoma, 2018 Jul, Volume 59, Issue 7, p.1574-1585, (2018)
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494., Winter, Jane N., Li Shuli, Aurora Vikas, Variakojis Daina, Nelson Beverly, Krajewska Maryla, Zhang Lijun, Habermann Thomas M., Fisher Richard I., Macon William R., et al. , Clin Cancer Res, 2010 Apr 15, Volume 16, Issue 8, p.2435-42, (2010)
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas., Bayliss, Jill, Mukherjee Piali, Lu Chao, Jain Siddhant U., Chung Chan, Martinez Daniel, Sabari Benjamin, Margol Ashley S., Panwalkar Pooja, Parolia Abhijit, et al. , Sci Transl Med, 2016 Nov 23, Volume 8, Issue 366, p.366ra161, (2016)
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia., Saba, Nakhle S., Wong Deanna H., Tanios Georges, Iyer Jessica R., Lobelle-Rich Patricia, Dadashian Eman L., Liu Delong, Fontan Lorena, Flemington Erik K., Nichols Cydney M., et al. , Cancer Res, 2017 Dec 15, Volume 77, Issue 24, p.7038-7048, (2017)
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia., Ribeiro, Ana Flávia Ti, Pratcorona Marta, Erpelinck-Verschueren Claudia, Rockova Veronika, Sanders Mathijs, Abbas Saman, Figueroa Maria E., Zeilemaker Annelieke, Melnick Ari, Löwenberg Bob, et al. , Blood, 2012 Jun 14, Volume 119, Issue 24, p.5824-31, (2012)
Outcome of deferred initial therapy in mantle-cell lymphoma., Martin, Peter, Chadburn Amy, Christos Paul, Weil Karen, Furman Richard R., Ruan Jia, Elstrom Rebecca, Niesvizky Ruben, Ely Scott, Diliberto Maurizio, et al. , J Clin Oncol, 2009 Mar 10, Volume 27, Issue 8, p.1209-13, (2009)
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905., Prebet, Thomas, Sun Zhuoxin, Figueroa Maria E., Ketterling Rhett, Melnick Ari, Greenberg Peter L., Herman James, Juckett Mark, Smith Mitchell R., Malick Lisa, et al. , J Clin Oncol, 2014 Apr 20, Volume 32, Issue 12, p.1242-8, (2014)
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies., Elstrom, Rebecca L., Martin Peter, Ostrow Katya, Barrientos Jacqueline, Chadburn Amy, Furman Richard, Ruan Jia, Shore Tsiporah, Schuster Michael, Cerchietti Leandro, et al. , Clin Lymphoma Myeloma Leuk, 2010 Jun, Volume 10, Issue 3, p.192-6, (2010)
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction., Wilkinson, Adam C., Ballabio Erica, Geng Huimin, North Phillip, Tapia Marta, Kerry Jon, Biswas Debabrata, Roeder Robert G., C Allis David, Melnick Ari, et al. , Cell Rep, 2013 Jan 31, Volume 3, Issue 1, p.116-27, (2013)